San Diego-centered Viking Therapeutics marked itself as a significant competitor in the weight loss drug industry in February following revealing promising knowledge from the mid-stage demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when supplied as a weekly injection and in March the company